Physician perceptions of GLP-1 receptor agonists in the UK

Current Medical Research and Opinion
Louis S MatzaKristina S Boye

Abstract

Objectives Glucagon-like peptide-1 (GLP-1) receptor agonists have been used to treat type 2 diabetes for almost a decade, and new treatments in this class have recently been introduced. The purpose of this study was to examine perceptions of GLP-1 receptor agonists among physicians who treat patients with type 2 diabetes in the UK. Methods A total of 670 physicians (226 diabetes specialists; 444 general practice [GP] physicians) completed a survey in 2014. Results Almost all physicians had prescribed GLP-1 receptor agonists (95.4% total sample; 99.1% specialists; 93.5% GP), most frequently to patients whose glucose levels are not adequately controlled with oral medications (85.9% of physicians) and obese/overweight patients (83.7%). Physicians' most common reasons for prescribing a GLP-1 receptor agonist were: associated with weight loss (65.8%), good efficacy (55.7%), less hypoglycemia risk than insulin (55.2%), not associated with weight gain (34.5%), and better efficacy than oral medications (32.7%). Factors that most commonly cause hesitation when prescribing this class were: not considered first line therapy according to guidelines (56.9%), injectable administration (44.6%), cost (36.7%), gastrointestinal side effects (33....Continue Reading

References

Apr 21, 2004·The Diabetes Educator·Martha M FunnellMary Spencer
Aug 16, 2005·The Diabetes Educator·David C ZiemerLawrence S Phillips
Sep 28, 2005·Diabetes Care·William H PolonskySteven V Edelman
Apr 9, 2008·International Journal of Clinical Practice·R P HayesS J Jacober
Nov 29, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Meryl BrodTorsten L Christensen
Apr 13, 2011·Diabetes/metabolism Research and Reviews·Vanita R Aroda, Robert Ratner
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier
Jan 22, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·G C HallP D Home
Sep 28, 2013·Canadian Journal of Diabetes·Hasina Visram
Feb 14, 2015·Therapeutic Advances in Endocrinology and Metabolism·Jennifer M TrujilloSamuel L Ellis

❮ Previous
Next ❯

Citations

Aug 5, 2016·Postgraduate Medicine·John E AndersonLuis-Emilio Garcia-Perez
Aug 29, 2018·Diabetes Care·Antonios DourosLaurent Azoulay
Dec 7, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Irene RomeraJesús Reviriego
Oct 28, 2019·Diabetes, Obesity & Metabolism·Louis S MatzaLuis-Emilio García-Pérez
Dec 15, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·K WinkleyE Holmes-Truscott
May 23, 2019·Drugs in R&D·Kristina S BoyeLuis-Emilio García-Pérez
Jul 17, 2021·Frontiers in Endocrinology·Baptist Gallwitz, Francesco Giorgino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

The Annals of Pharmacotherapy
Sarah L Anderson, Jennifer M Trujillo
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Anne Ottney
The Journal of the American Osteopathic Association
Jeffrey S Freeman
© 2021 Meta ULC. All rights reserved